YAHOO FINANCE CHARTBOOK 44 charts that explain markets and the economy right now Frankfurt - Delayed Quote • EUR Bicycle Therapeutics plc (50BA.F) Follow Compare 11.90 -0.20 (-1.65%) At close: January 31 at 3:29:01 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 50BA.F 1D 5D 1.71% 1M -10.53% 3M -44.91% 6M -46.88% YTD -10.53% 1Y -25.63% 5Y 24.61% All 7.50% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 50BA.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) First Solar, Frontier Communications, and More Stocks See Action From Activist Investors Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025? Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference Related Tickers 7UM.F Ultimovacs ASA 0.1742 -2.02% 6XP.SG Xspray Pharma AB (publ) 2.8600 +5.93% 4YL.F Nanoform Finland Oyj 1.2100 -0.17% 471A.F aTyr Pharma, Inc. 3.5800 +3.47% IMR.F AC Immune SA 2.5200 +1.82% 5CV.F CureVac N.V. 3.6520 -1.78% CARA Cara Therapeutics, Inc. 4.8400 -3.39%